Trials / Completed
CompletedNCT07009600
Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer
Impact of Targeted Therapy and Immune Checkpoint Inhibitors on Prognosis and Surgical Outcomes in Conversion Surgery for Stage IV Gastric Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 124 (actual)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
In this retrospective study, investigators conducted a comprehensive investigation of the factors influencing postoperative prognosis in patients with stage IV gastric cancer undergoing conversion surgery. Specifically, investigators examined the impact of targeted therapy or immune check point inhibitors (ICIs) in combination with preoperative chemotherapy on (1) prognostic differences based on initial progression (invading adjacent organs) and metastatic site (peritoneum, distant lymph node \[LN\]) at the time of stage IV gastric cancer diagnosis and (2) conversion surgery outcomes and pathological complete response (pCR).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | immune check point inhibitors (PD-1 inhibitors), target therapy (trastuzumab) |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2025-06-06
- Last updated
- 2025-06-06
Source: ClinicalTrials.gov record NCT07009600. Inclusion in this directory is not an endorsement.